[HTML][HTML] A randomized, placebo-controlled, multicenter, biomarker-selected, Phase 2 study of apricoxib in combination with erlotinib in patients with advanced non …
BJ Gitlitz, E Bernstein, ES Santos, GA Otterson… - Journal of Thoracic …, 2014 - Elsevier
Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in non–
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell …
BJ Gitlitz, E Bernstein, ES Santos… - Journal of thoracic …, 2014 - pubmed.ncbi.nlm.nih.gov
Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in non-
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell …
BJ Gitlitz, E Bernstein, ES Santos… - Journal of Thoracic …, 2014 - europepmc.org
Abstract Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in
non–small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth …
non–small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth …
[HTML][HTML] A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non …
BJ Gitlitz, E Bernstein, ES Santos… - Journal of thoracic …, 2014 - ncbi.nlm.nih.gov
Abstract Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in
non–small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth …
non–small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth …
[PDF][PDF] A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non …
BJ Gitlitz, E Bernstein, ES Santos, GA Otterson… - Journal of Thoracic …, 2014 - core.ac.uk
Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in non–
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell …
BJ Gitlitz, E Bernstein, ES Santos… - Journal of …, 2014 - ohiostate.elsevierpure.com
Abstract Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in
non-small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …
non-small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …
[HTML][HTML] A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non …
BJ Gitlitz, E Bernstein, ES Santos, GA Otterson… - Journal of Thoracic …, 2014 - jto.org
Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in non–
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …